Amid Strong 2013 Results from Ironwood Pharma (IRWD), Near-Term Profitability Remains Elusive - Analyst

January 21, 2014 11:54 AM

Aegis Capital reiterates its Buy rating and $16 price target on Ironwood Pharma (Nasdaq: IRWD) following fiscal 2013 results reported ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found